Clinical News

Beyond Beta-Blockers: Ivabradine for CHFReview of new drug Ivabradine (Corlanor) approved by the FDA for the management of heart failure.
FDA approves lixisenatide for type 2 diabetesNew drug review
Pharmacies Look to Add Value By Offering Tuberculosis TestingAs community pharmacies strive to play a greater role in population health management, could TB testing be an important item on the service menu?
A Class of Their Own: The Unique Challenges of Type I DiabetesWhile many aspects of diabetes care are universal, patients with type I diabetes (T1D) often face a unique set of obstacles and challenges.
Ixazomib for multiple myelomaFDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone
FDA approves Epclusa (sofosbuvir/velpatasvir) for chronic hepatitis C infectionFDA approved EpclusaTM (sofosbuvir and velpatasvir, (SOF-VEL) for adults with chronic hepatitis C infection both with compensated cirrhosis or without cirrhosis as well as in combination with ribavirin for hepatitis C with decompensated cirrhosis.
Update on Diabetes TherapyDespite evidence that optimal glycemic control can help reduce disease progression and complications, most patients do not achieve recommended treatment goals.
Study Finds Oral Syringes Better for Liquid Pediatric MedsA randomized controlled study has found that oral syringes are more accurate than dosing cups when parents measure doses of liquid medications for their children.
Pharmacist involvement key in heart risk screeningPharmacists’ involvement in cardiovascular risk screening resulted in referrals to physicians for patients who were under-diagnosed.
Eligible infants not getting rotavirus vaccineResearchers found that estimated coverage for RV at 19 to 35 months of age lags behind the other vaccines recommended at ages two, four, and six.